Navigation Links
Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
Date:9/8/2010

ALEXANDRIA, Va., Sept. 8 /PRNewswire/ -- Oxford Finance Corporation (Oxford), a subsidiary of Sumitomo Corporation, is pleased to announce the addition of Dr. Killu Sanborn to its Business Development group. As director, Business Development, she is responsible for originating loan facilities for life science companies, primarily in western North America.

She has over 20 years of experience as a lender and equity investor, banker, executive and entrepreneur. Her previous positions include managing director at Hercules Technology Growth Capital, senior vice president of Comerica Bank, principal/fund manager at IngleWood Ventures, director of Technology Commercialization at Stratagene and vice president of Business Development at Phenogenex. Over the years, Dr. Sanborn has also advised entrepreneurial boards and management teams on operational, financial and strategic matters.

"Dr. Sanborn is well-known and highly respected in the life science arena," said Christopher A. Herr, managing director for Oxford Finance Corporation. She brings with her a deep understanding of the financing needs of life science companies and will be a great asset to our Business Development team."

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm that provides senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $1.5 billion in loans, with lines of credit ranging from $500 thousand to $40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California, Massachusetts and North Carolina. For more information visit www.oxfordfinance.com.


'/>"/>
SOURCE Oxford Finance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
2. Oxford BioTherapeutics Appoints Michael Moore as Chairman
3. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
4. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
5. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
6. Bavarian Nordics Case Against Oxford BioMedica
7. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
8. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
9. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
10. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
11. Matan Companies Teams with Federal Capital Partners to Finance the National Cancer Institute at Riverside Research Park in Frederick, Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):